MGUS study on a cohort population referred by primary care to a DGH in North Kent aiming to develop a proposed predictive tool for risk progression and optimise referral triage and monitoring pathways

Monoclonal Gammopathy of Undetermined Significance (MGUS) is a precursor to multiple myeloma, yet many challenges remain in its management. These include better identifying high-risk patients, developing personalised treatment plans, and addressing the emotional and practical impacts on patients. Current risk models have limitations, and ongoing research aims to improve early detection, monitoring, and patient support to enhance outcomes and quality of life.

Outputs

Early days, results to be seen.